ClinicalTrials.gg
TerminatedNCT06206278Updated Aug 14, 2024

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

A Phase 2 interventional study of Infigratinib in Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by LianBio LLC. Terminated at 30 sites in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by LianBio LLC · Phase 2, Interventional, and Treatment

Why this study was terminated
Business Reason

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,184 studies in Stomach Neoplasms with a site in China — 481 open to participants now, 557 under way, 50 of them phase 3. Stomach Neoplasms · China.

Enrollment
863rd of 881
6 · median 87
Started
2023
with 111 others
Phase 2
323 of 1,184
133 open now
Registered
783rd of 1,184
by date

Among the 1,184 studies in Stomach Neoplasms with a site in China, this one is the 863rd largest by enrollment of the 881 interventional ones that give a count, is one of 112 that started in 2023, is one of 323 in phase 2, and was the 783rd registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

481 of the 1,184 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

476 more — sign in →

All 481 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,184 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label, single arm phase II study to evaluate the efficacy and safety of Infigratinib in patients with locally advanced or metastatic GC or GEJ patient with FGFR2 gene amplification, who have failed at least 2 lines of previous standard systemic treatment .

03

Conditions studied

  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Browse trials for

Keywords

  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • FGFR2
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years and older
  • or cytologically confirmed locally advanced or gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma.
  • Failed at least 2 lines of prior systemic therapy
  • Willing to undergo tumor or provide FFPE samples for central lab testing.
  • At least one measurable tumor lesion by v1.1
  • (ECOG) performance status of 0 or 1.
  • ≥3 months.
  • Willing to participate in this study and sign form, able to read and understand the study, follow the procedures.

Exclusion criteria

Exclusion Criteria:

  • History of other primary within 3 years except adequately treated in situ carcinoma of the cervix or non-melanoma carcinoma of the skin or any other curatively treated malignancy that is not expected to require treatment for recurrence during the study.
  • Previous or current treatment of a mitogen-activated protein kinase (MAPK-MEK) or selective FGFR inhibitor.
  • Any known to infigratinib or its .
  • History and/or current evidence of extensive tissue calcification.
  • Current evidence of endocrine alterations of calcium/phosphate homeostasis.
  • Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral infigratinib (such as, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).14. Laboratory abnormality as defined in protocol.
  • Considered unsuitable to participate in the study by Investigator
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Infigratinib

    Infigratinib 125 mg orally daily, 3 weeks on, 1 week off. . In patients with mild liver function abnormalities or mild renal impairment, the starting dose is 100 mg.

    Drug: Infigratinib

Interventions

  • Infigratinib is a selective ATP-competitive inhibitor of fibroblast growth factor receptor (FGFR) 1-3 that inhibits FGFR downstream signaling and proliferation in human cancer cell lines with FGFR genetic alterations, significantly inhibiting the growth of several types of cancers driven by FGFR amplification, fusion and mutation.

    Also known as: BGJ398, BBP-831

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    ORR: the proportion of patients with confirmed complete response (CR) or partial response (PR), assessed by the independent review committee (IRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.

    Time frame: Week9/17/25/33 and every 12 weeks after (up to 2 years)

  2. Duration of response (DoR)

    DoR: the duration from the first evaluation as CR or PR to the first evaluation as progressive disease (PD) or death of any cause, per RECIST v1.1 assessed by investigator (INV) and IRC.

    Time frame: Week9/17/25/33 and every 12 weeks after (up to 2 years)

  3. Disease control rate (DCR)

    DCR: the proportion of patients whose overall response is confirmed to be CR or PR or stable disease (SD) per RECIST v1.1, assessed by INV and IRC.

    Time frame: Week9/17/25/33 and every 12 weeks after (up to 2 years)

  4. Investigator evaluated ORR

    the proportion of patients with confirmed CR or PR assessed by INV according to RECIST v1.1

    Time frame: Week9/17/25/33 and every 12 weeks after (up to 2 years)

  5. Progression-free survival (PFS)

    the duration from the first date of treatment to the date of progression or death due to any cause, assessed by INV and IRC

    Time frame: Week9/17/25/33 and every 12 weeks after (up to 2 years)

  6. Overall survival (OS)

    from the first date of Infigratinib treatment until date of death.

    Time frame: from the first date of Infigratinib treatment until date of death.

07

Study locations

30 sites
  • Anhui Provincial Cancer Hospital
    Hefei, Anhui 230031, China
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Beijing Cancer Center
    Beijing, Beijing Municipality 100142, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
  • The Second Hospital Lanzhou University
    Lanzhou, Gansu 730030, China
  • Dongguan City People's Hospital
    Dongguan, Guangdong 523059, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong 510180, China
  • The Sixth Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510655, China
  • The Second Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi 541199, China
  • Liuzhou People's Hospital
    Liuzhou, Guangxi 545006, China
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 071030, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Tongji Hospital, Tongji Medical College of HUST
    Wuhan, Hubei 430030, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Hunan Provincial People's Hospital
    Changsha, Hunan 410002, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130012, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110002, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi, China
  • Central Hospital Affiliated to Shandong First Medical University
    Jinan, Shandong 250013, China
  • Shandong Provincial Cancer Hosptial
    Jinan, Shandong 250117, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
  • Zhongshan Hospital Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030013, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Sichuan Cancer Hospital
    Chengdu, Sichuan 610042, China
  • Tianjin Medical University Cancer Institute&Hospital
    Tianjin, Tianjin Municipality 300060, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650118, China
  • The First Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310013, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in May 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Jan 16, 2024
StartActual
Oct 19, 2023
Primary completionActual
May 31, 2024
CompletionActual
May 31, 2024
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06206278
Lead sponsor
LianBio LLC
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
Oct 19, 2023
Primary completion
May 31, 2024
Completion
May 31, 2024
Last update
Aug 14, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infigratinib

Start the discussion